Search Results

You are looking at 1 - 10 of 417 items for :

  • All content x
Clear All
Full access

Joyce Y. Wong and Vernon K. Sondak

excision of melanoma Evaluate different methods for the biopsy of melanoma and the role of expert pathologists Analyze surgical practices for melanoma Assess how to manage nevi among patients with melanoma Surgical removal remains the mainstay of

Full access

George Plitas and Charlotte E. Ariyan

Lymph nodes are often the first site of melanoma metastases, and the presence of metastatic disease in the draining lymph node is the most powerful predictor of survival in patients with clinical stage I and II disease. 1 , 2 The field of

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Overview In 2010, an estimated 68,130 new cases of melanoma were diagnosed and approximately 8700 patients died of the disease in the United States. 1 However, these figures for new cases may represent a substantial underestimation, because

Full access

Allan C. Halpern and Sanjay K. Mandal

Cancer J Clin 2005 ; 55 : 10 – 30 . 2. de Vries E Coebergh JW . Melanoma incidence has risen in Europe . BMJ 2005 ; 331 : 698 . 3. Welch HG Woloshin S Schwartz LM . Skin biopsy rates and incidence of melanoma: population based

Full access

Richard D. Carvajal, Sharon A. Spencer, and William Lydiatt

Mucosal melanoma (MM) is an aggressive and clinically complex malignancy made more challenging by its relative rarity. Of the 68,130 cases of melanoma diagnosed in 2010 in the United States, only 0.8% to 1.8% of these arise from mucosal surfaces

Full access

Robert H. I. Andtbacka and Jeffrey E. Gershenwald

Buzaid AC Soong SJ . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma . J Clin Oncol 2001 ; 19 : 3635 – 3648 . 4 Balch CM Soong SJ Gershenwald JE . Prognostic factors analysis of 17,600 melanoma

Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States. 1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ

Full access

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

Full access

Michael S. Sabel and Sandra L. Wong

Edited by Kerrin G. Robinson

relevant financial relationships. References 1 Balch CM Soong SJ Gershenwald JE . Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001

Full access

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

the express written permission of the NCCN © 2009. Disclosures for the NCCN Melanoma Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through